Evotec: EUR 465 Million in the Bank — and EUR 111 Million That Flowed Out of the Business in Six Months

There is an investor weakness that loves fallen favorites: the anchoring effect. Your mind remembers a price it once saw and measures everything afterwards against it. Evotec shares hit a high of EUR 21.42 in 2024 and closed 2025 at EUR 5.45 on December 30 — a decline of roughly 33 percent in that year alone. If the old anchor is still in your head, "cheap" arrives automatically. But the anchor says nothing about the business. It only says something about your memory.

So let us make a deal: we set the old price aside and read together what Evotec SE (Frankfurt Prime Standard: EVT) actually reported — the Integrated Annual Report 2025, the interim statement for the first quarter of 2026, the July 13, 2026 release in which the company cut its own full-year outlook, and the half-year report of August 13, 2026, which makes the numbers behind it final.

That names the central tension of this analysis, and it runs through every chapter: Evotec is a real drug discovery factory with real customers and real AI capability — but the order book is shrinking, the rebuild costs money, and the well-stocked cash box was filled by asset sales and a convertible bond rather than by the business itself.

What Evotec Actually Does

Evotec does not develop its own medicines all the way to the pharmacy shelf. The Hamburg-based company is the service provider of drug discovery — the factory where others have their molecules searched for, tested and manufactured. When a pharmaceutical group has an idea for a drug but does not want to maintain the labs and the specialists for it, it buys that part in. From Evotec.

The business runs in two segments. Discovery & Preclinical Development (D&PD) is the large one: compound discovery, profiling, preclinical development, plus the ADME-Tox services of its Cyprotex subsidiary. That segment produced external revenue of EUR 528.9 million in 2025. Just – Evotec Biologics (JEB) is the smaller but technically more spectacular one: design and continuous manufacturing of biologics, with EUR 259.4 million of revenue in 2025.

As of December 31, 2025 the group employed 4,553 people across 14 sites in eight countries (prior year: 4,827 employees). By June 30, 2026 the average headcount was down to 4,461 — 296 fewer than the twelve-month 2025 average of 4,757, a decline of 6.2 percent versus year end. The half-year report names two reasons: the divestiture of Just – Evotec Biologics EU in December 2025 and the workforce reductions under Horizon. The customer list is impressive nonetheless: all twenty of the largest pharmaceutical companies, more than 800 biotechs, plus foundations and academic institutions. The fiscal year equals the calendar year.

The shares trade in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005664809, SDAX and TecDAX indices) and additionally as American Depositary Shares on Nasdaq under the ticker EVO. One point matters for any comparison: as of December 31, 2025 there were 177,778,907 shares in Frankfurt against 355,557,814 ADS — one share equals two ADS. Anyone comparing New York prices with Frankfurt prices has to carry that factor of two along. As of June 30, 2026 the count stood at 177,909,559 shares; the small increase came solely from exercised stock options.

How the Stock Landed on Our Desk

Not through a scanner hit, but through other people's attention: on August 4, 2026 Evotec appeared on the wallstreet-online forum ranking of the most discussed stocks among German retail investors. That is not a buy signal. It is a sign that many people share the same question — and for a stock that issued a convertible bond and then cut its full-year outlook within eight weeks, the question is an obvious one. On August 13, 2026 the company delivered the full half-year report; this analysis has been brought up to that date.

One constraint belongs right here, because it shapes the rest of the analysis: no market data was available for this article. Every figure in this text comes from an original report or a mandatory disclosure by the company. We therefore do not quote a current market capitalization — the last documented value is the market capitalization of EUR 0.969 billion as of December 31, 2025 from the annual report. Anything beyond that would be an estimate, and estimates have no place in an analysis.

The Numbers Over the Years — Honestly Appraised

Let us start with what genuinely impresses. In five years Evotec has built a revenue base most European biotech companies can only dream about: from EUR 618.0 million (2021) through 751.4 (2022), 781.4 (2023) and 797.0 (2024) to EUR 788.4 million in 2025. That is not a workshop, that is industry. And customer loyalty is high: repeat business — the share of recurring revenue from existing customers — was 90 percent in 2025, after 94 percent the year before.

The chart above, however, shows the second series, and it runs the other way. Adjusted group EBITDA — the company's operating earnings measure, adjusted for one-off items — fell from EUR 107.3 million (2021) through 101.7 and 66.4 to EUR 22.6 million (2024) and recovered to EUR 41.1 million in 2025. Translated: on practically unchanged revenue, less than half of what stuck in 2021 sticks today.

The bottom line for 2025 was a net loss of EUR 103.5 million after a loss of EUR 196.1 million the year before — an improvement of EUR 92.6 million, but still a loss. Earnings per share came in at minus EUR 0.58 after minus EUR 1.11. Research and development funded by Evotec itself fell to EUR 37.5 million after EUR 50.9 million in the prior year and EUR 70.2 million in 2022.

A rule of thumb for the rest of this analysis: at a service provider, flat revenue is not a plateau — it is an order book that is not growing back.

Uncomfortable Truth No. 1: The Company's Own Guidance Fell by up to EUR 170 Million

On May 6, 2026 Evotec published first-quarter figures and confirmed full-year guidance: EUR 700 to 780 million of revenue and adjusted group EBITDA of EUR 0 to plus 40 million. A little more than two months later, on July 13, 2026, the ad-hoc announcement arrived with new numbers.

The new markers for fiscal 2026: group revenue of approximately EUR 570 to 610 million (EUR 595 to 635 million at constant exchange rates) and adjusted group EBITDA of approximately minus EUR 70 to 105 million (minus EUR 60 to 90 million at constant rates). Against the old guidance, EUR 170 million is missing at the top of the revenue range and EUR 130 million at the bottom — and an earnings figure between zero and plus 40 million became a loss of up to EUR 105 million.

For the first half of 2026 the company first reported preliminary revenue of EUR 300.1 million and adjusted group EBITDA of minus EUR 42.7 million. First-half 2025 revenue was EUR 371.2 million. The half-year report of August 13, 2026 confirmed both to the euro — revenue of EUR 300,123 thousand and adjusted group EBITDA of minus EUR 42,684 thousand — and explicitly reaffirmed the full-year guidance. At segment level: Discovery & Preclinical Development delivered EUR 108.1 million in the second quarter (down 15.8 percent) and EUR 227.9 million in the first half (down 15.2 percent); Just – Evotec Biologics EUR 35.4 million in the second quarter (down 17.4 percent) and EUR 72.3 million in the first half (down 29.3 percent).

The report does carry one sentence the ad-hoc release did not: against the backdrop of the updated 2026 outlook, Evotec is currently reviewing its mid-term financial targets. Translated: not only the current year is being recalculated, but also the path to wherever the company intended to stand in 2028 or 2030. Anyone still carrying the old mid-term numbers is carrying a figure the company itself has just put up for revision.

The explanation for the guidance cut is remarkable because it is so precise. Evotec splits the revenue gap into three parts: approximately 40 percent shifts into 2027 within existing partnerships — revised phasing and adjusted milestone schedules. Approximately 45 percent relates to contributions from potential new strategic partnerships that are still under negotiation. Approximately 15 percent is attributable to lower-than-expected revenue conversion.

That matters in both directions. If 45 percent of the gap comes from contracts that have not been signed, the old guidance was to a significant extent a hope — and hopes are not an order book. On the other hand: net sales in the D&PD base business excluding strategic partnerships rose approximately 28 percent year over year in the first half of 2026. The operating foundation is growing, just not fast enough to replace the large deals that failed to arrive.

Uncomfortable Truth No. 2: In the First Half of 2026 the Work Cost More Than It Brought In

The half-year report of August 13, 2026 delivered a number the July ad-hoc release did not carry — and it is the most important one in the whole document. Group gross profit was negative: minus EUR 3.1 million, after plus EUR 50.4 million in the first half of 2025.

Gross profit sounds technical, but it asks the simplest question there is: after the direct costs of delivering the work are subtracted, is anything left of the revenue? For a building contractor it would be "contract value minus materials and the crew's wages." At Evotec, in the first half of 2026, the answer was no. EUR 300.1 million of revenue stood against EUR 303.3 million of cost of revenue.

"Cost of revenue for the six months ended June 30, 2026 amounted to € 303.3 m compared with € 320.9 m in the corresponding period of 2025, resulting in a gross margin of (1.0)% (6M 2025: 13.6%)."

— Evotec SE, Interim Statement 6M 2026, "Report on the financial situation and results" (published August 13, 2026)

The segment view shows where it binds. In the large Discovery & Preclinical Development segment the gross margin fell from 15.3 to 4.4 percent — the report cites the continued underutilization Horizon is meant to fix. At Just – Evotec Biologics it slid from plus 9.1 to minus 18.3 percent; here the one-off Sandoz license sale from the first quarter of 2025 is missing, joined by delayed program activities and temporarily higher material and project costs.

A service provider with EUR 449.8 million of property, plant and equipment — labs, instruments, production lines — cannot simply cut its way out of a weak order book: the rooms stand there, the freezers run, the specialists are on the payroll. That is the mechanism behind the negative gross margin, and it is why utilization, not revenue alone, is the decisive measure at Evotec.

The bottom line adds up to a net loss of EUR 168.6 million after EUR 75.1 million in the prior-year half. Net result per share came in at minus EUR 0.95 after minus EUR 0.42. Worth noting: that figure already includes a EUR 71.9 million book gain from selling the Tubulis stake to Gilead Sciences. Without that one-off income the loss would have been materially larger. The operating loss — the line before all financial and investment effects — was EUR 234.7 million after EUR 47.8 million a year earlier.

Uncomfortable Truth No. 3: Three Customers, 43 Percent of Revenue

Customer concentration is one of those terms you only feel through an everyday image. Imagine a neighbor telling you his company is doing splendidly, and then you learn that three customers bring in nearly half the money. Would you swallow hard for a second? That is exactly what sits in Evotec's risk report.

"In 2025, 43% of the Company's revenue came from three customers, and 74 customer alliances each generated over € 1 m."

— Evotec SE, Integrated Annual Report 2025, risk report

Two further numbers from the same report sharpen the picture. The contribution of the ten largest customers to total revenue rose from 52 percent (2024) to 61 percent (2025) — dependency increased noticeably in a single year. And the number of customer alliances generating more than EUR 1 million a year fell from 109 to 74. Two customers are named as contributing more than 10 percent of group revenue each: Bristol Myers Squibb and Sandoz.

With Sandoz there is an additional twist: in December 2025 Evotec sold that same customer its own biologics site in Toulouse — for a purchase price of roughly $350 million, plus claims to more than $300 million from future development and license payments. The largest customer is at the same time the largest buyer of company assets. That is not an accusation, but a structure worth knowing about.

How close the tie is shows up in one line of the notes: contract liabilities from advance payments by the largest customer stood at EUR 214,985 thousand on December 31, 2025 (prior year: EUR 215,108 thousand). That is roughly 27 percent of a full year of revenue — money already received, work still owed.

The half-year report of August 13, 2026 no longer breaks that item out by customer, but it does show the total: contract liabilities fell from EUR 250.2 million to EUR 205.1 million, because more revenue was earned than new upfront payments were received. That is the friendly reading of the move — the advance is being worked off. The unfriendly one sits next to it in the same balance sheet: trade and other receivables fell from EUR 136.0 million to EUR 96.4 million, mainly through cash receipts under the Sandoz license agreement signed in December 2025. Together the two lines say: less new work is coming in behind it.

Uncomfortable Truth No. 4: The Rebuild Costs Before It Saves

On March 10, 2026 Evotec announced "Horizon" — the next stage of a transformation begun in 2024. The core in one sentence: the global site network shrinks from 14 to ten sites, scientific work is concentrated in centers of excellence, and the commercial organization is recut.

The arithmetic behind it is public. The structural measures are meant to save roughly EUR 75 million a year by the end of 2027; for the 2026 to 2028 period the company expects cash restructuring costs of approximately EUR 100 million. Roughly 20 to 30 percent of the savings should already materialize in 2026 — Evotec reaffirmed that in its July 13, 2026 release.

"For the three months ended March 31, 2026, Evotec recorded reorganization costs totaling € 75.0 m."

— Evotec SE, Interim Statement 3M 2026, section 5 "Project Horizon" (published May 6, 2026)

EUR 75.0 million in a single quarter — precisely the sum the program is supposed to save in a full year. Of that, EUR 56.4 million related to personnel measures including severance payments and EUR 14.9 million to impairment losses on property, plant and equipment. Accordingly the first-quarter 2026 net loss came in at EUR 121.9 million after EUR 31.6 million in the prior-year quarter.

The second quarter continued the pattern. For the first half of 2026 as a whole, the report of August 13 shows EUR 98.9 million of reorganization costs — the prior-year half carried a small credit of EUR 0.6 million. That is only part of the roughly EUR 100 million of cash restructuring costs planned through 2028: provisions as of June 30, 2026 still hold EUR 48.6 million for personnel measures and EUR 10.6 million for restoration obligations on exited leases — money that has yet to leave the account.

One item outside the reorganization line belongs beside it, because it tells the same story: when management decided in June 2026 to market a laboratory building at the Hamburg headquarters for sublease, an impairment loss of EUR 42.3 million was recognized on it. That is the main reason other operating expenses jumped from EUR 5.6 million to EUR 51.2 million. In total Evotec wrote down EUR 81.5 million of property, plant and equipment during the half year; the carrying amount fell from EUR 554.6 million to EUR 449.8 million. A company that wants to sublet lab space at its own home base is saying something about its own utilization.

The balance sheet reacted immediately. Equity fell from EUR 813.7 million (December 31, 2025) via EUR 699.6 million (March 31, 2026) to EUR 665.6 million as of June 30, 2026, and the equity ratio from 47.5 to 42.3 percent. Total assets shrank from EUR 1,713.9 million to EUR 1,574.0 million. To be fair: a ratio of 42.3 percent is not an alarm level — plenty of industrial companies would be glad to have it. But EUR 148.1 million of equity in six months is not nothing either.

"Total stockholders' equity decreased by € 148.1 m to € 665.6 m (December 31, 2025: € 813.7 m) predominantly as a result of the net loss of the six months ended June 30, 2026 of € 168.6 m."

— Evotec SE, Interim Statement 6M 2026, "Stockholders' equity" (published August 13, 2026)

Anyone who wants to see how expensive such a gap between story and cash can get will find the extreme case in our analysis of Recursion Pharmaceuticals: a billion-dollar narrative against quarterly revenue in the single-digit millions. Evotec is nowhere near that — it earns real money from real customers. But the mechanics are the same: narrative and cash flow run on different clocks.

Uncomfortable Truth No. 5: The Money in the Vault Did Not Come From the Business

Now to the cash, the bulls' strongest argument — and the place where reading two lines further pays off. Group liquidity rose during 2025 from EUR 396.8 million to EUR 476.4 million. As of December 31, 2025 Evotec was even debt-free on a net basis: net debt stood at minus EUR 27.7 million, which is a net cash position, after net debt of plus EUR 42.6 million a year earlier.

The condensed cash flow statement in the same report shows where it came from:

• Net cash used in operating activities: minus EUR 9.2 million (2024: plus EUR 18.2 million)
• Net cash from investing activities: plus EUR 171.6 million (2024: minus EUR 71.2 million)
• Net cash used in financing activities: minus EUR 37.6 million

The entire increase therefore sits in the investing column — essentially the sale of the Toulouse site to Sandoz. Day-to-day operations cost money in 2025 rather than producing it. In the first quarter of 2026 operating cash flow was minus EUR 3.9 million and liquidity fell by EUR 31.6 million to EUR 444.8 million.

Then came the half-year report. It shows an operating cash outflow of EUR 111.1 million for the first six months of 2026. For scale, because the number otherwise slips past: that is more than twelve times the entire prior year and twenty-one times the prior-year half.

"Net cash provided by (used in) operating activities in the first six months ended June 30, 2026 was € (111.1) m compared with € (5.3) m in the first six months 2025. This year's figure was largely driven by lower operating performance."

— Evotec SE, Interim Statement 6M 2026, chapter 2 "Cash flows and financial position" (published August 13, 2026)

That the cash box nevertheless held almost steady comes down to two offsetting entries. First, the sale of the stake in Tubulis GmbH to Gilead Sciences brought in EUR 89.3 million net — the transaction closed on May 21, 2026 for total consideration of EUR 93.7 million, of which 5.25 percent went to the European Investment Bank. Second, financing contributed EUR 33.8 million net: EUR 112.9 million of inflows from the convertible bond and other loans against EUR 76.3 million of loan and lease repayments.

Total liquidity therefore fell only from EUR 476.4 million to EUR 465.6 million. Pure cash and cash equivalents, however, dropped from EUR 418.5 million to EUR 348.4 million; the difference sits in current investments such as money market funds, which rose from EUR 57.9 million to EUR 117.2 million. Read only the headline "EUR 465.6 million of liquidity" and you see a stable cash position. Put the cash flow statement next to it and you see how much selling and financing it took to make it look stable.

The starting point for that financing was May 12, 2026. Evotec placed convertible bonds of EUR 116.1 million due 2033, with a coupon of 2.625 percent per year and redemption at 110 percent of principal. The initial conversion price is EUR 6.5313 — a premium of 37.5 percent over the reference share price of EUR 4.75; taking the accreted redemption amount into account, the effective conversion price is around EUR 7.1844. Shareholders' pre-emptive rights were excluded. The stated purpose: funding the liquidity needs of the Horizon program.

Dilution in everyday terms: your slice of the cake gets smaller because new slices are being cut. Let us do the arithmetic. EUR 116.1 million divided by EUR 6.5313 gives roughly 17.78 million potential new shares — measured against the 177,778,907 shares outstanding on December 31, 2025, that is exactly 10.0 percent. For comparison: total 2025 dilution from exercised stock options was 0.335 percent.

The half-year report shows the bond on the balance sheet for the first time. It is carried as a compound instrument: the debt component lifted financial liabilities by EUR 104.5 million to EUR 475.9 million in total (December 31, 2025: EUR 448.7 million), while the equity component of EUR 8.4 million sits in additional paid-in capital. Nobody has converted so far — the share count rose only to 177,909,559 as of June 30, 2026, and solely through exercised employee options. The 10.0 percent of dilution potential has not gone away; it is still standing there.

A second half-sentence from the annual report belongs next to it, because it explains why the bond was needed at all: as of December 31, 2025 the company had no outstanding undrawn credit lines left — a year earlier there were EUR 75.1 million. The buffer next to the cash box was gone. The half-year report does not repeat that disclosure; only the annual report carries it.

One important counter-check to close this chapter: the half-year report states explicitly that it was prepared on the basis that the group will continue to operate as a going concern, and that there are no material uncertainties casting significant doubt on that assumption. In a half year with a EUR 168.6 million loss, that is not a given — and it is the reason this analysis rates the situation as open rather than threatening.

The AI Story — and What the Report Actually Says

Many investors see Evotec as Germany's AI name in pharmaceutical research. That is not made up. The group explicitly names AI-driven innovation as the core of its strategy, and on June 2, 2026 it appointed a Head of Global In Silico & AI at executive vice president level. The Just – Evotec Biologics service catalogue contains a concrete, sellable offering: antibody molecular optimization and candidate selection using state-of-the-art in silico-based AI tools (J.MD).

On August 6, 2026 another data point arrived, and it is the most tangible yet: Odyssey Therapeutics is paying Evotec to use its AI-enabled data science. That is the difference between "we use AI" and "somebody buys our AI" — and for classifying this company, it is the decisive one.

"Under the agreement, Odyssey will leverage Evotec's integrated data-driven discovery platform, advanced screening capabilities and AI-enabled data science technologies to discover and validate differentiated small molecule drug candidates across multiple high-value disease targets."

— Evotec SE, press release of August 6, 2026

For a sober assessment one caveat matters: little is known about the terms. Evotec is eligible for milestone payments on the successful delivery of validated hit series for each target; no amounts were disclosed. For the 2026 revenue line, that is not yet a number — it is an option.

"Our new strategy tightens the focus on technology and science leadership, specifically in AI-driven innovation, molecular glue degraders, and targeted protein degradation, aiming to maximize impact in high-value segments."

— Evotec SE, Integrated Annual Report 2025, strategy chapter

It gets interesting a few pages later, in the risk report. AI appears there a second time — on the other side of the table. Emerging AI-driven biotechs, the report says, present growing competitive threats; these AI-focused companies are competing for deals and partnerships with major pharmaceutical firms and may enhance their wet lab capabilities, increasing competition in drug discovery.

That is the most honest passage in the whole document. The same technology that makes Evotec's offering better also lowers the barrier to entry for competitors — and pricing pressure comes on top of it from cost-conscious contract research organizations in Asia and Eastern Europe. If you find molecular glue degraders an intriguing future theme, you can see the same bet at a pure-play developer in our analysis of Monte Rosa Therapeutics; Evotec already earns money from that technology today, but it also carries the service provider's risk.

What the Stock Costs — and What We Cannot Say

Here we deliberately stay coarse and explicitly dated. The last documented market value comes from the annual report: EUR 0.969 billion as of December 31, 2025, at a year-end closing price of EUR 5.45 (December 30, 2025) and 177,778,907 shares. Measured against 2025 revenue of EUR 788.4 million, that is a price-to-sales ratio of roughly 1.2. A price-to-earnings ratio cannot be formed — 2025 ended in a loss.

What we cannot say, we do not say: no market data was available for this analysis, so a current market capitalization and every ratio derived from it are missing. If you need them, your broker has them — and you should keep in mind that three things have changed since December 31, 2025 that affect the calculation: the EUR 116.1 million convertible bond, the lowered full-year guidance, and equity that fell by EUR 148.1 million to EUR 665.6 million in the first half of 2026.

One reference point still holds: at expected 2026 revenue of EUR 570 to 610 million, the revenue base sits roughly a quarter below the 2025 level. Anyone valuing the stock on 2025 metrics is valuing a company that no longer exists at that size in the current year.

One special item belongs in the same calculation, and the half-year report now makes it exact: the acquisition of its portfolio company Tubulis by Gilead Sciences — Evotec held 3.14 percent through its venture arm — closed on May 21, 2026 for total consideration of EUR 93.7 million, of which 5.25 percent went to the European Investment Bank, leaving EUR 89.3 million net. The EUR 71.9 million book gain sits inside the half-year result. On top of that comes contingent consideration of up to roughly $58 million upon achievement of certain milestones. That is a one-time inflow, not recurring revenue — it strengthens the cash box, not the business model.

One more line from the half-year report belongs in the valuation, because it works with a long fuse: research funded by Evotec itself fell in the first half of 2026 to EUR 20.3 million from EUR 29.4 million a year earlier — from 7.9 to 6.8 percent of revenue. The report calls it more focused capital allocation. For the cost line, that is good. For the company's own pipeline, which is supposed to produce the high-margin milestones one day, it is the second lean year in a row.

Opportunities and Risks at a Glance

Opportunities

• The base business is growing again: net sales in the D&PD base business excluding strategic partnerships rose more than 28 percent year over year in the first half of 2026 — confirmed with the half-year report of August 13, 2026. Evotec expects the higher commercial activity to translate into revenue from the fourth quarter of 2026 onwards.
• The balance sheet carries the rebuild: EUR 665.6 million of equity and a 42.3 percent equity ratio (June 30, 2026), EUR 465.6 million of liquidity, and the report still describes the position as net liquidity. The going concern basis is explicitly confirmed without material uncertainties.
• Horizon is quantified, dated and delivering first savings: roughly EUR 75 million of structural annual savings by the end of 2027, of which 20 to 30 percent already in 2026 — reaffirmed on August 13, 2026 with the note that savings already realized in the first half strengthen confidence in that target.
• One-time inflows support the cash position: roughly $350 million from the sale of the Toulouse site to Sandoz (December 2025) plus claims of more than $300 million from future development, as well as EUR 89.3 million net from the Tubulis sale to Gilead (May 2026) and up to roughly $58 million of contingent consideration.
• The customer base is first-rate: all twenty of the largest pharmaceutical companies, more than 800 biotechs, and 90 percent repeat business in 2025. On August 6, 2026 Odyssey Therapeutics joined as a new partner in an AI-enabled research collaboration.

Risks

• Group gross margin was negative in the first half of 2026: minus 1.0 percent after plus 13.6 percent. At Just – Evotec Biologics it was minus 18.3 percent, at Discovery & Preclinical Development 4.4 percent after 15.3 percent.
• Operating cash outflow rose to EUR 111.1 million in the first half of 2026, after EUR 5.3 million in the prior-year half. Liquidity only held because EUR 89.3 million arrived from the Tubulis sale and EUR 112.9 million from the convertible bond and other loans.
• The 2026 guidance was cut on July 13, 2026 and reaffirmed on August 13, 2026: revenue of EUR 570 to 610 million instead of EUR 700 to 780 million, adjusted group EBITDA of minus EUR 70 to 105 million instead of EUR 0 to plus 40 million. Roughly 45 percent of the gap depends on partnerships that are still under negotiation. The mid-term financial targets are now under review as well.
• Customer concentration: 43 percent of 2025 revenue from three customers, the top-ten share up from 52 to 61 percent, and the number of alliances above EUR 1 million down from 109 to 74.
• Dilution potential of 10.0 percent from the EUR 116.1 million convertible bond (conversion price EUR 6.5313); financial liabilities rose to EUR 475.9 million, and there were no undrawn credit lines left as of December 31, 2025 (prior year: EUR 75.1 million).
• The rebuild costs first: EUR 98.9 million of reorganization costs in the first half of 2026, plus a EUR 42.3 million impairment on a laboratory building at the Hamburg headquarters, and roughly EUR 100 million in cash terms from 2026 to 2028. Equity fell by EUR 148.1 million within six months.
• The company's own risk report names AI-driven biotechs as growing competition and cites pricing pressure from contract research organizations in Asia and Eastern Europe; the half-year report describes the risk picture as mainly unchanged from the 2025 annual report.
• The comprehensive evaluation of strategic options at group level, initiated on May 6, 2026, runs without a timetable; the company explicitly states that no decision has been made and that no outcome can be assured. A member of the audit and compliance committee also stepped down from the supervisory board effective August 7, 2026.

A Human Conclusion

We started with the anchoring effect — with the EUR 21.42 high from 2024 that sticks in your head and makes every later number look small. After this walk through the filings, one thing can be said: the anchor is the wrong yardstick. Not because the stock is expensive or cheap, but because the company behind it is a different one today. A group with EUR 797 million of revenue and 14 sites is becoming one with an expected EUR 570 to 610 million and ten sites. The old price referred to the old company.

What remains is an honest double message. Evotec has something many biotech names do not: real customers, real revenue, a balance sheet with a 42.3 percent equity ratio and EUR 465.6 million of liquidity — and a half-year report that confirms the going concern basis explicitly and without material uncertainties. And Evotec simultaneously has a problem no restructuring solves quickly: the large, high-margin partnerships are not landing at the pace its own planning assumed — and the business with many smaller customers does not yet cover the gap.

The test we had marked in the calendar has now come and gone: on August 13, 2026 the full half-year figures arrived, and in three places they landed harder than the July ad-hoc release had suggested. First, gross margin was negative. Second, EUR 111.1 million flowed out of operations instead of the EUR 9.2 million of the entire prior year. Third, the company is now putting its mid-term financial targets up for review as well. On the other side, the 28 percent of base business growth is confirmed, as is the Horizon timetable — and with the collaboration of August 6, 2026, somebody has paid for the AI capability everyone else only talks about.

The next date is November 5, 2026, with the nine-month statement. That is when we learn whether the higher commercial activity reaches the revenue line from the fourth quarter as promised, and how much liquidity the rebuild consumed in the third quarter. Until then: if you read this analysis and say "too many open questions," you have understood the filings correctly. If you say "precisely because of that — the base business is turning," you have understood them correctly too, just with a different risk appetite. What you make of it is your decision. And that is exactly as it should be.

You will find more deep dives in our research section.

Sources

• Evotec SE — Interim Statement 6M 2026 (PDF), published August 13, 2026: highlights, chapter 1 "Results of operations", chapter 2 "Cash flows and financial position", chapter 3 "Assets, liabilities, and stockholders' equity", chapter 4 "Human Resources", income statement, balance sheet, statement of cash flows, Note 2 "Basis of Preparation", Note 4 "Significant Events", Note 8 "Property, Plant and Equipment", Note 10 "Earnings per Share", Note 11 "Restructuring Provision", Note 16 "Subsequent Events"
• Evotec SE — press release "Evotec Reports Second Quarter and First Half 2026 Results: Building Commercial Momentum", August 13, 2026: quarterly and half-year segment tables, reaffirmed 2026 outlook, review of mid-term financial targets, quotes from CEO Dr. Christian Wojczewski and CFO Claire Hinshelwood, supervisory board change effective August 7, 2026
• Evotec SE — press release "Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases", August 6, 2026: scope of the collaboration, milestone-based compensation, quote from the chief scientific officer
• Evotec SE — Integrated Annual Report 2025 (English and German editions): the Evotec share, key financial performance indicators, management report (results of operations, financial position, condensed cash flow statement), strategy, risk and opportunity report, notes on contract liabilities and share capital
• Evotec SE — Interim Statement 3M 2026, published May 6, 2026: results of operations, financial position, assets/liabilities/equity, section 5 "Project Horizon", events after the reporting period
• Evotec SE — first-quarter 2026 results release, May 6, 2026: Horizon update, initiation of the comprehensive evaluation of strategic options at group level (advisors Morgan Stanley and Moelis & Company), leadership changes
• Evotec SE — press release "Evotec SE Successfully Placed EUR 116.1 Million Convertible Bonds", May 12, 2026: terms, conversion price, use of proceeds
• Evotec SE — "Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook", July 13, 2026 (published as an ad-hoc announcement at the same time)
• Evotec SE — appointment of the Head of Global In Silico & AI, June 2, 2026, and results of the annual general meeting 2026, June 11, 2026
• Evotec SE — investor relations, financial publications and news overview, own retrievals on August 4 and August 13, 2026: the Interim Statement 6M 2026 has been available since August 13, 2026 and the nine-month statement is scheduled for November 5, 2026. There was no separate half-year webcast — the company points to the recording, slides and transcript of the July 14, 2026 webcast

This analysis is journalistic commentary based on publicly available documents. It is not investment advice, not a solicitation to buy or sell securities, and not a personal recommendation. Shares can lose substantial value, and a total loss of the capital invested is possible. Every figure carries the reporting date of its source; no current market capitalization is quoted because no market data was available. Positions held by the operator are disclosed daily; where one exists, it appears as a notice at the top of this deep dive.